ScreenerHero

FULC Fulcrum Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · fulcrumtx.com
3.670USD-0.54%Mkt Cap: 280.01M $P/E: —

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United St…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap280.01M USD
Enterprise Value-32.03M USD
Revenue (TTM)—
Gross Profit-56.10M USD
Net Income (TTM)-74.88M USD
Revenue/Share—
Last Price3.670 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees9
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.74
PEG—
EV/EBITDA0.38
EV/Revenue—
P/S—
P/B0.91
EPS (TTM)-1.20
EPS (Forward)-0.55
52W Range
2.9106% of range15.74
52W High15.74 USD
52W Low2.910 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-21.46%
ROA-20.44%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-60.06M USD
CapEx (TTM)314.00K USD
FCF Margin—
FCF Yield-13.35%
Net Debt-313.56M USD
Net Debt/EBITDA3.67
Balance Sheet
Debt/Equity0.02
Current Ratio31.35
Quick Ratio31.16
Book Value/Sh4.07 USD
Cash/Share4.18 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)3.667 USD
Upside (mean)-0.1%
Target Range3.000 USD – 4.000 USD
3.000-0.1% to mean4.000
# Analysts3
Ownership
Shares Out.76.30M
Float63.49M
Insiders3.35%
Institutions102.96%
Short Interest
Short Ratio4.2d
Short % Float9.53%
Short % Out.9.43%
Shares Short7.19M
Short (prev mo.)6.66M
Technical
SMA 503.782 (-3.0%)
SMA 2006.568 (-44.1%)
Beta2.63
S&P 52W Chg16.45%
Avg Vol (30d)1.64M
Avg Vol (10d)1.51M
Technical Indicators
RSI (14)38.5
MACD-0.0334
MACD Signal-0.0239
MACD Hist.-0.0095
BB Upper3.870 USD
BB Middle3.756 USD
BB Lower3.643 USD
BB Width6.05%
ATR (14)0.0723 USD
Vol Ratio (20d)0.75x